Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Imlunestrant is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wildtype and Mutant Breast Cancer.
Bhagwat SV, Mur C, Vandekopple M, Zhao B, Shen W, Marugán C, Capen A, Kindler L, Stephens JR, Huber L, Castanares MA, Garcia-Tapia D, Cohen JD, Bastian J, Mattioni B, Yuen E, Baker TK, Rodriguez Cruz V, Fei D, Manro JR, Pulliam N, Dowless MS, Ortiz Ruiz MJ, Yu C, Puca L, Klippel A, Bacchion F, Ismail-Khan R, Rodrik-Outmezguine V, Peng SB, Lallena MJ, Gong X, de Dios A. Bhagwat SV, et al. Among authors: stephens jr. Cancer Res. 2024 Dec 9. doi: 10.1158/0008-5472.CAN-24-2608. Online ahead of print. Cancer Res. 2024. PMID: 39652577
Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA, Dowless MS, Iversen PW, Parsons S, Ellis KE, McCann DJ, Pelletier J, Furic L, Yingling JM, Stancato LF, Sonenberg N, Graff JR. Konicek BW, et al. Among authors: stephens jr. Cancer Res. 2011 Mar 1;71(5):1849-57. doi: 10.1158/0008-5472.CAN-10-3298. Epub 2011 Jan 13. Cancer Res. 2011. PMID: 21233335
Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
Lowery CD, Blosser W, Dowless M, Knoche S, Stephens J, Li H, Surguladze D, Loizos N, Luffer-Atlas D, Oakley GJ 3rd, Guo Q, Iyer S, Rubin BP, Stancato L. Lowery CD, et al. Clin Cancer Res. 2018 Feb 15;24(4):847-857. doi: 10.1158/1078-0432.CCR-17-1258. Epub 2017 Nov 30. Clin Cancer Res. 2018. PMID: 29191969
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells.
Litchfield LM, Boehnke K, Brahmachary M, Mur C, Bi C, Stephens JR, Sauder JM, Gutiérrez SM, McNulty AM, Ye XS, Wu W, Lallena MJ, Gong X, Merzoug FF, Jansen VM, Buchanan SG. Litchfield LM, et al. Among authors: stephens jr. Oncotarget. 2020 Apr 28;11(17):1478-1492. doi: 10.18632/oncotarget.27539. eCollection 2020 Apr 28. Oncotarget. 2020. PMID: 32391118 Free PMC article.
Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling.
Dowless M, Lowery CD, Shackleford T, Renschler M, Stephens J, Flack R, Blosser W, Gupta S, Stewart J, Webster Y, Dempsey J, VanWye AB, Ebert P, Iversen P, Olsen JB, Gong X, Buchanan S, Houghton P, Stancato L. Dowless M, et al. Clin Cancer Res. 2018 Dec 1;24(23):6028-6039. doi: 10.1158/1078-0432.CCR-18-1256. Epub 2018 Aug 21. Clin Cancer Res. 2018. PMID: 30131386 Free PMC article.
LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.
Liu L, Zeng W, Wortinger MA, Yan SB, Cornwell P, Peek VL, Stephens JR, Tetreault JW, Xia J, Manro JR, Credille KM, Ballard DW, Brown-Augsburger P, Wacheck V, Chow CK, Huang L, Wang Y, Denning I, Davies J, Tang Y, Vaillancourt P, Lu J. Liu L, et al. Among authors: stephens jr. Clin Cancer Res. 2014 Dec 1;20(23):6059-70. doi: 10.1158/1078-0432.CCR-14-0543. Epub 2014 Sep 17. Clin Cancer Res. 2014. PMID: 25231402
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Lowery CD, Dowless M, Renschler M, Blosser W, VanWye AB, Stephens JR, Iversen PW, Lin AB, Beckmann RP, Krytska K, Cole KA, Maris JM, Hawkins DS, Rubin BP, Kurmasheva RT, Houghton PJ, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Erickson SW, Teicher BA, Smith MA, Stancato LF. Lowery CD, et al. Among authors: stephens jr. Clin Cancer Res. 2019 Apr 1;25(7):2278-2289. doi: 10.1158/1078-0432.CCR-18-2728. Epub 2018 Dec 18. Clin Cancer Res. 2019. PMID: 30563935 Free PMC article.
223 results